PTC Therapeutics | PTCT - Cash And Equivalent


PTC Therapeutics reported $672.62M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Incyte USD 2.93B 508.08M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025
Xencor USD 28.29M 16.15M Sep/2025